Merck & Co., Inc. $MRK Stock: Cantor Fitzgerald Investment Advisors L.P. Cuts Position

Key Points

• Cantor Fitzgerald Investment Advisors reduced its Merck position by 65.9% in the third quarter, selling 73,104 shares and retaining 37,907 shares valued at $5.5 million. Institutional investors collectively own 76.07% of MRK.
• Merck insiders sold 228,238 shares worth nearly $30 million over the past three months, while insiders retain only 0.17% of the company.
• Shares opened at $146.01, and analysts maintain a “Moderate Buy” consensus with an average price target of $151.92. Merck recently reported quarterly revenue of $16.61 billion and declared a quarterly dividend of $0.85 per share, a 2.3% annualized yield.

Cantor Fitzgerald Investment Advisors L.P. decreased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 65.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,907 shares of the company's stock after selling 73,104 shares during the period. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Merck & Co., Inc. were worth $5,508,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRK. BostonPremier Wealth LLC purchased a new stake in Merck & Co., Inc. in the third quarter valued at $218,000. Trail Ridge Investment Advisors LLC raised its stake in shares of Merck & Co., Inc. by 2.8% during the 3rd quarter. Trail Ridge Investment Advisors LLC now owns 5,579 shares of the company's stock worth $811,000 after buying an additional 153 shares during the last quarter. Goldstein Advisors LLC raised its stake in Merck & Co., Inc. by 41.1% in the 3rd quarter. Goldstein Advisors LLC now owns 6,258 shares of the company's stock valued at $909,000 after purchasing an additional 1,824 shares during the last quarter. Legacy Wealth Partners LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $218,000. Finally, Neumann Capital Management LLC purchased a new stake in shares of Merck & Co., Inc. during the third quarter worth about $1,239,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 10,000 shares of the business's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David R. Maraldo sold 18,706 shares of the firm's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last three months. Insiders own 0.17% of the company's stock.

Merck & Co., Inc. Trading Up 0.6%

Shares of Merck & Co., Inc. stock opened at $146.01 on Friday. The stock has a market capitalization of $360.22 billion, a P/E ratio of 116.81, a price-to-earnings-growth ratio of 6.71 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a 50-day simple moving average of $145.60 and a 200 day simple moving average of $129.24.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. During the same period last year, the firm posted $2.13 EPS. The business's revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts expect that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Wall Street Analyst Weigh In

MRK has been the subject of several analyst reports. Royal Bank Of Canada reduced their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a "sector perform" rating for the company in a research report on Monday, October 12th. Leerink Partners raised their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Barclays boosted their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Finally, Berenberg Bank boosted their target price on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a "hold" rating in a research report on Friday, September 11th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $151.92.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.